Nevogenesis pp 111-115 | Cite as

Nevogenesis: A Benign Metastatic Process?: An Update

  • Andrew L. Ross
  • Margaret I. Sanchez
  • James M. Grichnik
Chapter

Abstract

Cutaneous nevogenesis is largely considered a localized event that occurs exclusively in the dermis and/or epidermis. However, the presence of circulating nevocytes suggests that other, more systemic, benign metastatic processes could also contribute to nevogenesis. The theoretical role of lymphatic and hematogenous dissemination of loosely adherent, immature nevus progenitor cells in the development of nodal nevi and eruptive melanocytic nevi will be reviewed.

Keywords

BRAF V600E Mutation Melanocytic Nevus Hematogenous Dissemination Hematogenous Route Clonal Heterogeneity 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Conflict of Interest

DigitalDerm, Inc – major shareholder. Spectral Image, Inc – past grants and consulting. MELA Sciences, Inc – past grants and consulting. Genentech – consultant. Archives of Dermatology, skINsight – section editor.

References

  1. 1.
    Ross AL, Sanchez MI, Grichnik JM. Nevogenesis: a benign metastatic process? ISRN Dermatol. 2011;2011:813513.PubMedGoogle Scholar
  2. 2.
    Grichnik JM. Melanoma, nevogenesis, and stem cell biology. J Invest Dermatol. 2008;128(10):2365–80.PubMedCrossRefGoogle Scholar
  3. 3.
    Grichnik JM. Hypothesis letter: the reason sentinel and lymph node dissections do not improve melanoma mortality. J Invest Dermatol. 2009;129(3):779–81.PubMedCrossRefGoogle Scholar
  4. 4.
    Biddle DA, Evans HL, Kemp BL, et al. Intraparenchymal nevus cell aggregates in lymph nodes: a possible diagnostic pitfall with malignant melanoma and carcinoma. Am J Surg Pathol. 2003;27(5):673–81.PubMedCrossRefGoogle Scholar
  5. 5.
    Andreola S, Clemente C. Nevus cells in axillary lymph nodes from radical mastectomy specimens. Pathol Res Pract. 1985;179(6):616–8.PubMedCrossRefGoogle Scholar
  6. 6.
    Bautista NC, Cohen S, Anders KH. Benign melanocytic nevus cells in axillary lymph nodes. A prospective incidence and immunohistochemical study with literature review. Am J Clin Pathol. 1994;102(1):102–8.PubMedGoogle Scholar
  7. 7.
    Carson KF, Wen DR, Li PX, et al. Nodal nevi and cutaneous melanomas. Am J Surg Pathol. 1996;20(7):834–40.PubMedCrossRefGoogle Scholar
  8. 8.
    Fontaine D, Parkhill W, Greer W, Walsh N. Nevus cells in lymph nodes: an association with congenital cutaneous nevi. Am J Dermatopathol. 2002;24(1):1–5.PubMedCrossRefGoogle Scholar
  9. 9.
    Holt JB, Sangueza OP, Levine EA, et al. Nodal melanocytic nevi in sentinel lymph nodes. Correlation with melanoma-associated cutaneous nevi. Am J Clin Pathol. 2004;121(1):58–63.PubMedCrossRefGoogle Scholar
  10. 10.
    Howell BG, Lipa JE, Ghazarian DM. Intracapsular melanoma: a new pitfall for sentinel lymph node biopsy. J Clin Pathol. 2006;59(8):891–2.PubMedGoogle Scholar
  11. 11.
    Patterson JW. Nevus cell aggregates in lymph nodes. Am J Clin Pathol. 2004;121(1):13–5.PubMedCrossRefGoogle Scholar
  12. 12.
    De Giorgi V, Pinzani P, Salvianti F, et al. Circulating benign nevus cells detected by ISET technique: warning for melanoma molecular diagnosis. Arch Dermatol. 2010;146(10):1120–4.PubMedCrossRefGoogle Scholar
  13. 13.
    Abernethy JL, Soyer HP, Kerl H, Jorizzo JL, White WL. Epidermotropic metastatic malignant melanoma simulating melanoma in situ. A report of 10 examples from two patients. Am J Surg Pathol. 1994;18(11):1140–9.PubMedCrossRefGoogle Scholar
  14. 14.
    Lestre S, Joao A, Ponte P, et al. Intraepidermal epidermotropic metastatic melanoma: a clinical and histopathological mimicker of melanoma in situ occurring in multiplicity. J Cutan Pathol. 2011;38(6):514–20.PubMedCrossRefGoogle Scholar
  15. 15.
    Ross AL, Sanchez MI, Grichnik JM. Molecular nevogenesis. Dermatol Res Pract. 2011;2011:9.Google Scholar
  16. 16.
    Straume O, Sviland L, Akslen LA. Loss of nuclear p16 protein expression correlates with increased tumor cell proliferation (Ki-67) and poor prognosis in patients with vertical growth phase melanoma. Clin Cancer Res. 2000;6(5):1845–53.PubMedGoogle Scholar
  17. 17.
    Betlloch I, Amador C, Chiner E. Eruptive melanocytic nevi in human immunodeficiency virus infection. Int J Dermatol. 1991;30(4):303.PubMedCrossRefGoogle Scholar
  18. 18.
    Lopez V, Molina I, Martin JM, et al. Eruptive nevi in a patient receiving cyclosporine A for psoriasis treatment. Arch Dermatol. 2010;146(7):802–4.PubMedCrossRefGoogle Scholar
  19. 19.
    Bovenschen HJ, Tjioe M, Vermaat H, et al. Induction of eruptive benign melanocytic naevi by immune suppressive agents, including biologicals. Br J Dermatol. 2006;154(5):880–4.PubMedCrossRefGoogle Scholar
  20. 20.
    Barker JN, MacDonald DM. Eruptive dysplastic naevi following renal transplantation. Clin Exp Dermatol. 1988;13(2):123–5.PubMedCrossRefGoogle Scholar
  21. 21.
    Onsun N, Saracoglu S, Demirkesen C, Kural YB, Atilganoglu U. Eruptive widespread Spitz nevi: can pregnancy be a stimulating factor? J Am Acad Dermatol. 1999;40(5 Pt 2):866–7.PubMedGoogle Scholar
  22. 22.
    Lanschuetzer CM, Emberger M, Hametner R, et al. Pathogenic mechanisms in epidermolysis bullosa naevi. Acta Derm Venereol. 2003;83(5):332–7.PubMedCrossRefGoogle Scholar
  23. 23.
    Cardones AR, Grichnik JM. Alpha-melanocyte-stimulating hormone-induced eruptive nevi. Arch Dermatol. 2009;145(4):441–4.PubMedCrossRefGoogle Scholar
  24. 24.
    Sekulic A, Colgan MB, Davis MD, Dicaudo DJ, Pittelkow MR. Activating BRAF mutations in eruptive melanocytic nevi. Br J Dermatol. 2010;163(5):1095–8.PubMedCrossRefGoogle Scholar
  25. 25.
    Lin J, Takata M, Murata H, et al. Polyclonality of BRAF mutations in acquired melanocytic nevi. J Natl Cancer Inst. 2009;101(20):1423–7.PubMedCrossRefGoogle Scholar
  26. 26.
    Kim MY, Oskarsson T, Acharyya S, et al. Tumor self-seeding by circulating cancer cells. Cell. 2009;139(7):1315–26.PubMedCrossRefGoogle Scholar
  27. 27.
    Cochran AJ, Binder S, Morton DL. The role of lymphatic mapping and sentinel node biopsy in the management of atypical and anomalous melanocytic lesions. J Cutan Pathol. 2011;37 Suppl 1:54–9.Google Scholar
  28. 28.
    Zalaudek I, Guelly C, Pellacani G, et al. The dermoscopical and histopathological patterns of nevi correlate with the frequency of BRAF mutations. J Invest Dermatol. 2011;131(2):542–5.PubMedCrossRefGoogle Scholar
  29. 29.
    Capper D, Preusser M, Habel A, et al. Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody. Acta Neuropathol. 2011;122(1):11–9.PubMedCrossRefGoogle Scholar

Copyright information

© Springer- Verlag Berlin Heidelberg 2012

Authors and Affiliations

  • Andrew L. Ross
    • 1
  • Margaret I. Sanchez
    • 1
  • James M. Grichnik
    • 1
    • 2
    • 3
  1. 1.Department of Dermatology and Cutaneous SurgeryUniversity of Miami Miller School of MedicineMiamiUSA
  2. 2.Melanoma Program, Department of Dermatology and Cutaneous SurgerySylvester Comprehensive Cancer CenterMiamiUSA
  3. 3.Interdisciplinary Stem Cell Institute, Miller School of MedicineUniversity of MiamiMiamiUSA

Personalised recommendations